Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400332 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 281
- Enrollment target
NCT03400332 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 281 participants.
The verdict
NCT03400332, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 281 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Interventions
- OTHER Placebo
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG BMS-986253
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03400332
The ClinicalTrials.gov registry entry for NCT03400332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03400332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03400332 about?
NCT03400332 is a clinical study titled "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers". The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
What is the current status of trial NCT03400332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 281 participants. The study started on 2018-02-12. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT03400332?
The interventions under investigation include: Placebo (OTHER), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986253 (DRUG).
Who is sponsoring clinical trial NCT03400332?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.